Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Mimedx (MDXG) Net Cash Flow (2016 - 2026)

Mimedx's Net Cash Flow history spans 16 years, with the latest figure at -$6.3 million for Q1 2026.

On a quarterly basis, Net Cash Flow fell 415.04% to -$6.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $53.3 million, a 9.4% decrease, with the full-year FY2025 number at $61.7 million, up 164.31% from a year prior.
Net Cash Flow hit -$6.3 million in Q1 2026 for Mimedx, down from $24.0 million in the prior quarter.
Over the last five years, Net Cash Flow for MDXG hit a ceiling of $24.0 million in Q4 2025 and a floor of -$33.5 million in Q1 2024.
Historically, Net Cash Flow has averaged $4.9 million across 5 years, with a median of $2.7 million in 2022.
Biggest five-year swings in Net Cash Flow: plummeted 1316.09% in 2022 and later soared 1879.07% in 2024.
Tracing MDXG's Net Cash Flow over 5 years: stood at $2.7 million in 2022, then crashed by 68.5% to $836000.0 in 2023, then soared by 1879.07% to $16.5 million in 2024, then soared by 45.29% to $24.0 million in 2025, then tumbled by 126.41% to -$6.3 million in 2026.
Business Quant data shows Net Cash Flow for MDXG at -$6.3 million in Q1 2026, $24.0 million in Q4 2025, and $23.2 million in Q3 2025.